Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
出版年份 2021 全文链接
标题
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
作者
关键词
Bruton's tyrosine kinase (BTK) inhibitors, Ibrutinib, Off-target toxicities, Drug resistance, Combination therapy
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 229, Issue -, Pages 114009
出版商
Elsevier BV
发表日期
2021-11-23
DOI
10.1016/j.ejmech.2021.114009
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Novel BTK mutation in X-linked agammaglobulinemia: Report of a 17-year-old male
- (2021) Zoha Shaka et al. ALLERGOLOGIA ET IMMUNOPATHOLOGIA
- Emerging small-molecule inhibitors of the Bruton’s Tyrosine Kinase (BTK): current development
- (2021) Jiakuo Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
- (2021) H. Yesid Estupiñán et al. Frontiers in Cell and Developmental Biology
- Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
- (2021) Logan Good et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma
- (2021) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
- (2021) Billy Michael Chelliah Jebaraj et al. BLOOD
- Ibrutinib’s off-target mechanism: cause for dose optimization
- (2021) Sara M. Zimmerman et al. CANCER BIOLOGY & THERAPY
- Discovery of novel BTK PROTACs for B-Cell lymphomas
- (2021) Yunpeng Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase
- (2021) Dandan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
- (2020) Ola A. Elgamal et al. Journal of Hematology & Oncology
- Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
- (2020) Xu-Wen Guan et al. Cell Death & Disease
- ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2020) Peter Hillmen et al. Future Oncology
- Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
- (2020) Ronen Gabizon et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
- (2020) Bhawana George et al. Cancers
- The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
- (2020) Gabriela Pavlasova et al. HAEMATOLOGICA
- Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
- (2020) H. Yesid Estupiñán et al. Blood Advances
- Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2020) Carsten Utoft Niemann et al. BLOOD
- PROTAC: A promising technology for cancer treatment
- (2020) Xin Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
- (2020) Laura Ondrisova et al. Frontiers in Oncology
- Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML
- (2020) Si Li et al. BIOORGANIC CHEMISTRY
- Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
- (2020) Shenxin Zeng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PROTACs to address the challenges facing small molecule inhibitors
- (2020) Pedro Martín-Acosta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Managing toxicities of Bruton tyrosine kinase inhibitors
- (2020) Andrew Lipsky et al. Hematology-American Society of Hematology Education Program
- 1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase
- (2020) Soňa Krajčovičová et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
- (2019) Yifan Feng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
- (2019) Peter Martin et al. BLOOD
- Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL
- (2019) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis
- (2019) Chufeng Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK in CLL: Beyond Ibrutinib
- (2019) David A. Bond et al. Current Hematologic Malignancy Reports
- A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant Btk C481S mutation in B‐cell malignancies
- (2019) Fu Gui et al. BRITISH JOURNAL OF PHARMACOLOGY
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
- (2019) Simo Xia et al. Cellular & Molecular Immunology
- Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines
- (2019) Xiaofeng Guo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer
- (2019) Sayan Dutta Gupta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2019) Yunhang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of targeted protein degradation therapeutics
- (2019) Philip P. Chamberlain et al. Nature Chemical Biology
- PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
- (2019) Xiuyun Sun et al. BIOCHEMISTRY
- Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma
- (2019) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
- (2019) Eliana B. Gomez et al. BLOOD
- Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
- (2019) Jennifer Woyach et al. BLOOD
- The role of MYC in the transformation and aggressiveness of ‘indolent’ B-cell malignancies
- (2019) Daniel Filip et al. LEUKEMIA & LYMPHOMA
- Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2019) Bartosz Puła et al. Cancers
- Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
- (2019) Isha Kapoor et al. Cell Death & Disease
- Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors
- (2018) Zhen Zhang et al. ARCHIV DER PHARMAZIE
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Non-covalent inhibition of C481S Bruton’s tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL
- (2018) Sean D. Reiff et al. BLOOD
- Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
- (2018) Oshrat Hershkovitz-Rokah et al. BRITISH JOURNAL OF HAEMATOLOGY
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
- (2018) Ann E. Herman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
- (2018) Chengyuan Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the B cell receptor pathway in non-Hodgkin lymphoma
- (2018) Kelly Valla et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib
- (2018) Linyi Liu et al. Future Medicinal Chemistry
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- (2018) James J. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels
- (2018) Gabriela Pavlasova et al. LEUKEMIA
- Role of Bruton’s tyrosine kinase in B cells and malignancies
- (2018) Simar Pal Singh et al. Molecular Cancer
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Delineating the role of cooperativity in the design of potent PROTACs for BTK
- (2018) Adelajda Zorba et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
- (2018) John C. Byrd et al. Oncotarget
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Gambogic acid induces heme oxygenase-1 through Nrf2 signaling pathway and inhibits NF-κB and MAPK activation to reduce inflammation in LPS-activated RAW264.7 cells
- (2018) Jie Ren et al. BIOMEDICINE & PHARMACOTHERAPY
- Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
- (2018) Jan A. Burger et al. BLOOD
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
- (2018) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
- (2018) Ana Colado et al. Blood Cancer Journal
- Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
- (2018) Matthew S Davids et al. Lancet Haematology
- Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines
- (2017) Dan Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia
- (2017) He Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
- (2017) J. J. Shatzel et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
- (2017) Hsu-Ping Kuo et al. MOLECULAR CANCER THERAPEUTICS
- The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition
- (2017) Gabriele Varano et al. NATURE
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
- (2017) Anella Yahiaoui et al. PLoS One
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- (2016) Adam R. Johnson et al. ACS Chemical Biology
- Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
- (2016) E. Gaudio et al. ANNALS OF ONCOLOGY
- HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
- (2016) Caron Jacobson et al. BLOOD
- Targeting BTK through microRNA in chronic lymphocytic leukemia
- (2016) A. Bottoni et al. BLOOD
- Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis
- (2016) G. Pavlasova et al. BLOOD
- Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
- (2016) D. E. Spaner et al. HAEMATOLOGICA
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Approaching resistance to ibrutinib in diffuse large B-cell lymphoma
- (2016) Tabea Erdmann et al. LEUKEMIA & LYMPHOMA
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
- (2016) Atish Mohanty et al. Oncotarget
- Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
- (2016) D. E. Spaner et al. HAEMATOLOGICA
- The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line
- (2015) Kazumi Hagiwara et al. APOPTOSIS
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
- (2015) P. Jain et al. BLOOD
- Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
- (2015) S. Sinha et al. CLINICAL CANCER RESEARCH
- Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
- (2015) M. Skarzynski et al. CLINICAL CANCER RESEARCH
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Perfluorooctane sulfonate mediates microglial activation and secretion of TNF-α through Ca2+-dependent PKC-NF-кB signaling
- (2015) Jianbin Yang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Src family kinases: at the forefront of platelet activation
- (2014) Y. A. Senis et al. BLOOD
- Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
- (2014) Jiao Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
- (2014) Jennifer A. Whang et al. DRUG DISCOVERY TODAY
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Celastrol Induces Apoptosis of Gastric Cancer Cells by miR-21 Inhibiting PI3K/Akt-NF-κB Signaling Pathway
- (2014) Min Sha et al. PHARMACOLOGY
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib
- (2014) Chung-Shien Lee et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia
- (2013) S. A. Rushworth et al. BLOOD
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients
- (2013) J Boysen et al. LEUKEMIA
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
- (2013) Rami Rahal et al. NATURE MEDICINE
- Inhibition of NF-κB activation is associated with anti-inflammatory and anti-apoptotic effects of Ginkgolide B in a mouse model of cerebral ischemia/reperfusion injury
- (2012) Jin-Hua Gu et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Tyrosine Kinase Btk Is Required for NK Cell Activation
- (2012) Yan Bao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Src, Syk, and Tec family kinases: Distinct types of molecular switches
- (2010) J. Michael Bradshaw CELLULAR SIGNALLING
- Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
- (2010) Julie A Di Paolo et al. Nature Chemical Biology
- Hsp90 and co-chaperones twist the functions of diverse client proteins
- (2009) Abbey Zuehlke et al. BIOPOLYMERS
- Vorinostat in solid and hematologic malignancies
- (2009) David Siegel et al. Journal of Hematology & Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started